OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Bone and Mineral Research is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III	190
Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop	110
Opportunistic Screening Using Low-Dose CT and the Prevalence of Osteoporosis in China: A Nationwide, Multicenter Study	105
Postpubertal Architectural Developmental Patterns Differ Between the L3 Vertebra and Proximal Tibia in Three Inbred Strains of Mice	96
Burosumab for the Treatment of Tumor-Induced Osteomalacia	86
Machine Learning Solutions for Osteoporosis—A Review	85
Bone Vasculature and Bone Marrow Vascular Niches in Health and Disease	84
Osteoporosis Management in the Era of COVID-19	84
Sclerostin Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of Elderly Women With Type 2 Diabetes	79
Skeletal Biology and Disease Modeling in Zebrafish	74
Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial	65
Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo-Controlled Trial	62
Bone Elasticity and Ultrasound Velocity Are Affected by Subtle Changes in the Organic Matrix	62
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases	60
The diverse origin of bone-forming osteoblasts	60
Racial and Ethnic Disparities in Bone Health and Outcomes in the United States	59
Piezo1 Inactivation in Chondrocytes Impairs Trabecular Bone Formation	58
Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism	52
Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study	51
The Effect of Fall Biomechanics on Risk for Hip Fracture in Older Adults: A Cohort Study of Video-Captured Falls in Long-Term Care	51
Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis	50
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study	48
Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia	47
Intracellular Accumulation of Advanced Glycation End Products Induces Osteoblast Apoptosis Via Endoplasmic Reticulum Stress	45
Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis	45

Runx2 Regulates Mouse Tooth Root Development Via Activation of WNT Inhibitor NOTUM	43
Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts	40
Single-Cell RNA Sequencing of Calvarial and Long-Bone Endocortical Cells	40
Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient Registry	39
Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post‐Fracture Treatment, and All‐Cause Mortality	39
Ectopic Calcification and Hypophosphatemic Rickets: Natural History of ENPP1 and ABCC6 Deficiencies	38
Metabolomics Insights into Osteoporosis Through Association With Bone Mineral Density	38
Sex- and Site-Specific Reference Data for Bone Microarchitecture in Adults Measured Using Second-Generation HR-pQCT	37
Fgf9 Negatively Regulates Bone Mass by Inhibiting Osteogenesis and Promoting Osteoclastogenesis Via MAPK and PI3K/AKT Signaling	37
Glutamine Metabolism in Osteoprogenitors Is Required for Bone Mass Accrual and PTH-Induced Bone Anabolism in Male Mice	37
Vitamin D and Muscle Health: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials	36
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With	36